Liminatus Pharma said on Friday it has completed its uplist to the Nasdaq Capital Market, joining the exchange widely used by growth-stage biotechnology firms.
The company’s shares began trading under the ticker symbol LIMX on the Nasdaq Capital Market on Friday, following approval from Nasdaq Listing Qualifications Department. The uplist marks a strategic shift for Liminatus, which previously traded on a lower-tier market.
Nasdaq Capital Market is designed to accommodate companies with smaller market capitalizations, offering a platform for access to broader investor pools and enhanced visibility. The move aligns with Liminatus’s growth trajectory in the biotechnology sector, where capital access and liquidity are critical for advancing pipeline development.
Liminatus Pharma did not disclose terms of the uplist or provide additional financial details in its announcement. The company’s prior trading venue was not specified.
